355 related articles for article (PubMed ID: 24460082)
1. Low but measurable stimulated serum thyroglobulin levels <2 µg/L frequently predict incomplete response in differentiated thyroid cancer patients.
Aldawish M; Jha N; McEwan AJ; Severin D; Ghosh S; Morrish DW
Endocr Res; 2014; 39(4):157-63. PubMed ID: 24460082
[TBL] [Abstract][Full Text] [Related]
2. Patients with differentiated thyroid cancer who underwent radioiodine thyroid remnant ablation with low-activity ¹³¹I after either recombinant human TSH or thyroid hormone therapy withdrawal showed the same outcome after a 10-year follow-up.
Molinaro E; Giani C; Agate L; Biagini A; Pieruzzi L; Bianchi F; Brozzi F; Ceccarelli C; Viola D; Piaggi P; Vitti P; Pacini F; Elisei R
J Clin Endocrinol Metab; 2013 Jul; 98(7):2693-700. PubMed ID: 23626005
[TBL] [Abstract][Full Text] [Related]
3. Radioiodine remnant ablation in low-risk differentiated thyroid cancer.
Saengsuda Y
J Med Assoc Thai; 2013 May; 96(5):614-24. PubMed ID: 23745318
[TBL] [Abstract][Full Text] [Related]
4. Impact of early vs late postoperative radioiodine remnant ablation on final outcome in patients with low-risk well-differentiated thyroid cancer.
Tsirona S; Vlassopoulou V; Tzanela M; Rondogianni P; Ioannidis G; Vassilopoulos C; Botoula E; Trivizas P; Datseris I; Tsagarakis S
Clin Endocrinol (Oxf); 2014 Mar; 80(3):459-63. PubMed ID: 23895145
[TBL] [Abstract][Full Text] [Related]
5. Age, thyroglobulin levels and ATA risk stratification predict 10-year survival rate of differentiated thyroid cancer patients.
Kelly A; Barres B; Kwiatkowski F; Batisse-Lignier M; Aubert B; Valla C; Somda F; Cachin F; Tauveron I; Maqdasy S
PLoS One; 2019; 14(8):e0221298. PubMed ID: 31425569
[TBL] [Abstract][Full Text] [Related]
6. Transient early increase in thyroglobulin levels post-radioiodine ablation in patients with differentiated thyroid cancer.
Stevic I; Dembinski TC; Pathak KA; Leslie WD
Clin Biochem; 2015 Jul; 48(10-11):658-61. PubMed ID: 25895485
[TBL] [Abstract][Full Text] [Related]
7. Application of post-surgical stimulated thyroglobulin for radioiodine remnant ablation selection in low-risk papillary thyroid carcinoma.
Vaisman A; Orlov S; Yip J; Hu C; Lim T; Dowar M; Freeman JL; Walfish PG
Head Neck; 2010 Jun; 32(6):689-98. PubMed ID: 20187016
[TBL] [Abstract][Full Text] [Related]
8. Baseline stimulated thyroglobulin level as a good predictor of successful ablation after adjuvant radioiodine treatment for differentiated thyroid cancers.
Fatima N; uz Zaman M; Ikram M; Akhtar J; Islam N; Masood Q; Zaman U; Zaman A
Asian Pac J Cancer Prev; 2014; 15(15):6443-7. PubMed ID: 25124640
[TBL] [Abstract][Full Text] [Related]
9. Serum thyroglobulin concentrations predict disease-free remission and death in differentiated thyroid carcinoma.
Heemstra KA; Liu YY; Stokkel M; Kievit J; Corssmit E; Pereira AM; Romijn JA; Smit JW
Clin Endocrinol (Oxf); 2007 Jan; 66(1):58-64. PubMed ID: 17201802
[TBL] [Abstract][Full Text] [Related]
10. Clinical outcome of low-risk differentiated thyroid cancer patients after radioiodine remnant ablation and recombinant human thyroid-stimulating hormone preparation.
Vianello F; Mazzarotto R; Mian C; Lora O; Saladini G; Servodio O; Basso M; Pennelli G; Pelizzo MR; Sotti G
Clin Oncol (R Coll Radiol); 2012 Apr; 24(3):162-8. PubMed ID: 21411300
[TBL] [Abstract][Full Text] [Related]
11. Recombinant human thyroid stimulating hormone-assisted radioactive iodine remnant ablation in thyroid cancer patients at intermediate to high risk of recurrence.
Hugo J; Robenshtok E; Grewal R; Larson S; Tuttle RM
Thyroid; 2012 Oct; 22(10):1007-15. PubMed ID: 22873801
[TBL] [Abstract][Full Text] [Related]
12. Long-term surveillance of papillary thyroid cancer patients who do not undergo postoperative radioiodine remnant ablation: is there a role for serum thyroglobulin measurement?
Durante C; Montesano T; Attard M; Torlontano M; Monzani F; Costante G; Meringolo D; Ferdeghini M; Tumino S; Lamartina L; Paciaroni A; Massa M; Giacomelli L; Ronga G; Filetti S;
J Clin Endocrinol Metab; 2012 Aug; 97(8):2748-53. PubMed ID: 22679061
[TBL] [Abstract][Full Text] [Related]
13. Timing of Radioactive Iodine Administration Does Not Influence Outcomes in Patients with Differentiated Thyroid Carcinoma.
Scheffel RS; Zanella AB; Dora JM; Maia AL
Thyroid; 2016 Nov; 26(11):1623-1629. PubMed ID: 27549175
[TBL] [Abstract][Full Text] [Related]
14. Effects of low-dose and high-dose postoperative radioiodine therapy on the clinical outcome in patients with small differentiated thyroid cancer having microscopic extrathyroidal extension.
Han JM; Kim WG; Kim TY; Jeon MJ; Ryu JS; Song DE; Hong SJ; Shong YK; Kim WB
Thyroid; 2014 May; 24(5):820-5. PubMed ID: 24328997
[TBL] [Abstract][Full Text] [Related]
15. Dynamic Risk Estimates of Outcome in Chinese Patients with Well-Differentiated Thyroid Cancer After Total Thyroidectomy and Radioactive Iodine Remnant Ablation.
Shen FC; Hsieh CJ; Huang IC; Chang YH; Wang PW
Thyroid; 2017 Apr; 27(4):531-536. PubMed ID: 28007013
[TBL] [Abstract][Full Text] [Related]
16. Radioiodine remnant ablation in differentiated thyroid cancer after combined endogenous and exogenous TSH stimulation.
Vrachimis A; Schober O; Riemann B
Nuklearmedizin; 2012; 51(3):67-72. PubMed ID: 22294096
[TBL] [Abstract][Full Text] [Related]
17. Outcomes of total thyroidectomy with therapeutic central and lateral neck dissection with a single dose of radioiodine in the treatment of regionally advanced papillary thyroid cancer and effects on serum thyroglobulin.
Hughes DT; Miller BS; Cohen MS; Doherty GM; Gauger PG
Ann Surg Oncol; 2014 May; 21(5):1647-52. PubMed ID: 24385210
[TBL] [Abstract][Full Text] [Related]
18. Papillary thyroid carcinomas with biochemical incomplete or indeterminate responses to initial treatment: repeat stimulated thyroglobulin assay to identify disease-free patients.
Lamartina L; Montesano T; Trulli F; Attard M; Torlontano M; Bruno R; Meringolo D; Monzani F; Tumino S; Ronga G; Maranghi M; Biffoni M; Filetti S; Durante C
Endocrine; 2016 Nov; 54(2):467-475. PubMed ID: 26668060
[TBL] [Abstract][Full Text] [Related]
19. Initial therapy with either thyroid lobectomy or total thyroidectomy without radioactive iodine remnant ablation is associated with very low rates of structural disease recurrence in properly selected patients with differentiated thyroid cancer.
Vaisman F; Shaha A; Fish S; Michael Tuttle R
Clin Endocrinol (Oxf); 2011 Jul; 75(1):112-9. PubMed ID: 21521273
[TBL] [Abstract][Full Text] [Related]
20. Value of stimulated serum thyroglobulin levels for detecting persistent or recurrent differentiated thyroid cancer in high- and low-risk patients.
Duren M; Siperstein AE; Shen W; Duh QY; Morita E; Clark OH
Surgery; 1999 Jul; 126(1):13-9. PubMed ID: 10418587
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
